MicroRNAs are key regulators of β-cell physiology. They participate to the differentiation of insulin-producing cells and are instrumental for the acquisition of their unique secretory properties. Moreover, they contribute to the adaptation of β-cells to conditions of increased insulin demand and, if expressed at inappropriate levels, certain microRNAs cause β-cell dysfunction and promote the development of different forms of diabetes mellitus. While these functions are increasingly better understood, additional tasks for these small non-coding RNAs have been recently unveiled. Thus, microRNAs are emerging as signaling molecules of a novel exosome-mediated cell-to-cell communication mode permitting a coordinated response of the β-cells to inflammatory conditions and to modifications in the insulin demand.
Introduction
Insulin is a central player in the control of glucose utilization and disposal. Indeed, this metabolic hormone promotes the uptake of this carbohydrate by skeletal muscles and adipocytes. Moreover, it inhibits hepatic glucose production and stimulates glycogen synthesis. In mammals, insulin is produced by pancreatic β-cells, a group of highly specialized cells located within the islets of Langerhans. The secretion of the hormone is modulated by nutrients and is fine-tuned by the integration of hormonal and neuronal cues [1] .
The amount of insulin that is released in the circulation is determined by the levels of free fatty acids, of certain amino acids and of glucose, which is the main physiological stimulus of β-cell exocytosis. Instead of binding to a receptor, glucose triggers the release of the hormone through the generation of metabolic signals. To achieve this goal, β-cells are equipped with a specific repertoire of metabolic enzymes ensuring a tight coupling between glucose metabolism and insulin secretion. In fully differentiated β-cells, the glycolytic products generated by glucose catabolism are preferentially driven to mitochondria for oxidative phosphorylation. The ATP generated by this reaction causes the closure of ATP-sensitive K + channels and a consequent depolarization of the plasma membrane [2] . This in turn triggers the opening of voltage-gated Ca 2+ channels and a rise in intracellular Ca 2+ concentration, finally leading to insulin exocytosis.
The amount of insulin released by β-cells is precisely adjusted to match the momentto-moment organism needs, permitting to maintain blood glucose homeostasis and to avoid chronic hyperglycemia or life-threatening hypoglycemic episodes. The sensitivity of insulintarget tissues is not constant throughout the entire lifespan and tends to decrease during aging [3] . Moreover, insulin-target tissues become resistant to the action of the hormone during pregnancy or obesity [4] . The consequent rise in the insulin needs is normally compensated by an increase in the mass and in the secretory activity of β-cells [4] . Failure in this adaptive process can result in the release of insufficient insulin to control blood glucose levels, leading to chronic hyperglycemia and to the development of diabetes mellitus, a very common metabolic disorder that is currently estimated to affect almost 400 million people worldwide (~8% of the adult world population). Due to population aging and a growing tendency to sedentary lifestyle and obesity, the number of individuals suffering from this disease is expected to further increase in the next decades.
An in depth understanding of the mechanisms governing the activities of β-cells under normal conditions and of those responsible for their failure under diabetic conditions is paramount for the discovery of novel innovative approaches to prevent or treat the disease.
This has made the β-cells the focus of intense investigations since decades. Most of the studies carried out so far searched for modifications in the level of key protein-coding genes occurring in the islets of diabetes animal models. This led to the identification of fundamental β-cell genes that are dysregulated in diabetes conditions. The involvement of at least part of these genes in human diabetes was confirmed by the study of the causes of monogenic forms of diabetes and by the discovery of variants that increase the susceptibility to the disease [5] .
However, protein-coding sequences represent only a tiny fraction of the human genome (about 2%) and we now know that most DNA sequences can be transcribed to RNA. Thus, beside mRNAs, the human transcriptome contains a very large repertoire of RNA molecules with no protein-coding potential. It is now clear that at least part of these non-coding molecules play central regulatory roles in a wide variety of physiological and pathological processes. Non-coding RNAs fall in different categories according to their length, biogenesis, genomic origin, binding partners and mode of action. This review will focus on a particular class of non-coding RNAs, the microRNAs (miRNAs). For a detailed description of the properties and functions of other non-coding transcripts produced by β-cells we refer the reader to other recent reviews [6, 7] .
miRNAs as regulators of specialized β-cell functions
MiRNAs are major regulators of gene expression. These small non-coding RNAs (21) (22) (23) nucleotides) function by partially pairing to the 3'untraslated region of target mRNAs, causing translational repression and/or a decrease in messenger stability [8] . Every miRNA can regulate many target genes and a specific target mRNA is often under the control of several distinct miRNAs. Thus, miRNAs form a complex regulatory network permitting the fine tuning of gene expression. The first evidence for an involvement of miRNAs in the control of β-cell activities was provided more than a decade ago by Poy et al. [9] . In this pioneering work, miR-375, a miRNA highly enriched in pancreatic islets, was demonstrated to inhibit the secretory activities of β-cells. Later on, the analysis of the phenotype of miR-375 knockout mice revealed that this miRNA is also necessary for compensatory β-cell mass expansion under insulin resistance conditions [10] . Moreover, miR-375 was discovered to play an even more important role in pancreatic α-cells. Indeed, miR-375 knockout animals display an increased α-cell mass and elevated glucagon levels, resulting in chronic hyperglycemia. The knockout of other miRNAs that are very abundant in β-cells caused also major changes in insulin secretion and glucose homeostasis. Indeed, miR-7a was shown to target important components of the exocytotic machinery of β-cells and to act as a negative regulator of insulin secretion [11] . Overexpression of this miRNA resulted in impaired insulin release and in the development of diabetes. On the other hand, ablation of the members of the miR-200 family improved survival of β-cells under stress conditions while their overexpression induced apoptosis and promoted the manifestation of diabetes [12] . These are only few examples of the many miRNAs that have been reported to inhibit the expression of key β-cell genes and/or to affect specialized activities of insulin-secreting cells. Exhaustive lists of miRNAs potentially contributing to the control of β-cell functions can be found elsewhere [13, 14] . Unfortunately, many of the studies investigating the role of specific miRNAs in β-cells were carried out only in cell lines or under experimental settings that are never observed under physiological or pathophysiological conditions. Thus, although potentially informative, some of these findings await further confirmation with more appropriate experimental approaches.
Involvement of miRNAs in β-cell differentiation and maturation
Pancreatic β-cells are highly specialized cells displaying unique functional features.
Differentiation of these cells occurs through a complex series of events that begins in the fetus and terminates only after weaning. There is now substantial evidence indicating that miRNAs are necessary for the differentiation of β-cells and for the acquisition of a fully mature phenotype. Indeed, pancreatic-specific deletion of Dicer1, the gene coding for the enzyme necessary for miRNA biogenesis, results in an almost complete absence of insulin-positive cells [15] . Moreover, the conditional knockout of Dicer1 in insulin-producing cells has a major impact on islet architecture and causes impaired glucose metabolism and defective insulin secretion [16, 17] . Although the full repertoire of miRNAs involved in β-cell differentiation remains to be defined, the contribution of some specific miRNAs has already been established. Indeed, embryonic knockdown of miR-375 in zebrafish causes defects in islet morphology and scattering of the endocrine cells in the developing pancreas [18] .
Moreover, re-expression of miR-375 permits to prevent dedifferentiation of human β-cells in culture [19] and the same miRNA favors the induction of insulin-producing cells from human embryonic stem cells by controlling the level of key transcription factors involved in pancreatic islet organogenesis [20] . Appropriate expression of miR-375 is also critical for fetal β-cell mass expansion. Indeed, fetuses of mothers fed with a low protein diet display increased levels of this miRNA with a consequent reduction of PDK1 expression and of the number of β-cells [21] . In contrast, miR-7 appears to be required for the survival of β-cells during early embryonic life. Indeed, blockade of this miRNA in mouse embryos using antisense morpholinos has a major impact on insulin production and decreases the number of β-cells, resulting in post-natal glucose intolerance [22] . Finally, embryonic induction of miR124a has been proposed to contribute to the generation of β-cells by repressing the transcription factor Forkhead box A2 (FOXA2) and permitting the expression of Pdx1 [23] .
While already capable of producing insulin and of releasing the hormone in response to certain secretagogues, newborn β-cells are unable to proliferate and to secrete insulin in a glucose-dependent manner until after weaning [24, 25] . Recent findings indicate that miRNAs contribute not only to the generation of insulin-expressing cells during the fetal life but participate also to the post-natal maturation of β-cells and to the acquisition of a fully mature phenotype. Newborn β-cells undergo major changes in the expression of metabolic genes permitting to acquire the capacity to respond to glucose. This gene reprogramming process is initiated by the nutritional shift occurring at weaning and is at least in part driven by changes in the expression of specific groups of miRNAs ( Fig.1) , including the miR-17-92 cluster and the miR-181 family [25] . Indeed, a reduction in the level of these miRNAs mimicking the modifications occurring at weaning was sufficient to render neonatal rat β-cells capable of secreting insulin in response to glucose.
MiRNAs participate in the adaptation of β-cells to increased insulin needs
The activity and the number of β-cells are constantly adjusted to match the insulin needs.
Short-term exposures to a rise in circulating levels of glucose, free fatty acids or amino acids enhance the secretory activity of β-cells [1] . In case of a sustained augmentation of the insulin needs, resulting from a drop in the sensitivity of peripheral tissues, the number of β-cells is also increased. MiRNAs appear to play a critical role in this adaptive process. In fact, as mentioned above, insulin-secreting cells fail to proliferate in obese leptin-deficient ob/ob mice lacking miR-375 [10] . Moreover, the compensatory expansion of the β-cell mass necessitates a reduction in the level of miR-184 and miR-338-3p. Indeed, the expression of these two miRNAs in pancreatic islets is diminished under insulin resistance conditions and blockade of miR-184 or miR-338-3p in β-cells enhance their proliferative rate both in vitro and in vivo [26] [27] [28] . There is also increasing evidence for the involvement of miR-132 in the mechanisms enabling the β-cell to face conditions necessitating the release of higher insulin quantities. In fact, the expression of this miRNA is strongly induced under insulin resistance conditions and upon exposure of the β-cells to GLP1 analogues or cAMP-raising agents [29] [30] [31] . A rise in the level of miR-132 improves glucose-induced insulin secretion and promotes β-cell proliferation and survival [30, 32, 33] .
The expression of several miRNAs is altered under diabetes conditions
Chronic hyperglycemia and hyperlipidemia induce major changes in gene expression causing the loss of specialized β-cell functions. Prolonged exposure of β-cells to saturated fatty acids such as palmitate was reported to increase the level of miR-34a and miR-146a [34] while several other miRNAs were shown to be modulated by glucose, including miR-9, miR-30d, miR-124a, miR-130a, miR-132, miR-133, miR-212 and miR-335 [35] [36] [37] [38] . Glucose was also found to decrease the level of miR-375 [39] but the effect of the carbohydrate on this miRNA remains controversial [36] . Alterations in miRNA expression were observed in the islets of several animal models of Type 2 diabetes, including the GK rats, ob/ob and db/db mice and mice fed a high fat diet [10-12, 28, 29, 32, 34, 36] . Moreover, aging and the loss of compensatory β-cell mass expansion was associated with changes in the rat islet miRNA profile [40] . In addition, modifications of islet miRNA expression were observed before the onset of Type 1 diabetes in NOD mice [41, 42] . Differential expression of specific miRNAs, including miR-7a, miR-124a, miR-187 and a cluster of miRNAs produced from an imprinted locus on chromosome 14q32, was also detected in the islets of human donors suffering from Type 2 diabetes [11, [43] [44] [45] . When reproduced in isolated β-cells, many of the changes in miRNA expression observed under diabetes conditions resulted in impaired insulin secretion and/or a decrease in cell survival, suggesting that the alterations in the miRNA profile contribute to β-cell failure and to the development of the disease.
Novel miRNA tasks
Beside their classical functions accomplished inside the cells producing them, few years ago, the role of miRNAs took another dimension with the discovery of the presence of these small RNAs in different biological fluids either in association with proteins [46] or lipoproteins [47] or packaged inside extracellular vesicles [48] . A large proportion of plasma miRNAs was found to be associated with ribonucleoprotein complexes, but a subset of specific miRNAs was detected only in microvesicles [46] . Nearly all cell types investigated so far were found to release microvesicles containing miRNAs that can be transferred in active form to recipient cells [48, 49] . Therefore, circulating miRNAs are now viewed as essential components of a new cell-to-cell communication mode whose rules and limitations remain to be defined.
Mammalian cells can release several types of vesicles, including exosomes, microvesicles and apoptotic bodies that possess distinct sizes and cargo composition and are probably involved in different biological processes [50] . Because of the rapid progress in the field and the exponential increase in the number of published articles, there is a lack of consensus in the isolation methods and in the microvesicle nomenclature. In this review, we will focus on fuse with the plasma membrane of the target cells and deliver their cargo in the cytoplasm or 3) be internalized and merge with endosomes to undergo transcytosis or to be targeted for degradation [54] (Fig.2) . Exosomes can travel in body fluids over long distances and carry proteins and nucleic acids that can be transferred to recipient cells [48, 55] . Thus, the study of these extracellular vesicles promises not only to improve the understanding of the mechanisms underlying intercellular and inter-organ communication but opens also new perspectives for the discovery of disease biomarkers.
The interest for exosomes has gained also the diabetes field [56] . Different research groups observed the release of exosome-like microvesicles from mouse, rat and human islets and from different β-cell lines [57] [58] [59] [60] [61] [62] . The analysis of the content of β-cell exosomes revealed the presence of both proteins and miRNAs [58] [59] [60] . Interestingly, the exosomal cargo differs when β-cell lines are treated with cytokines, suggesting that the signals carried by these extracellular vesicles contribute to the changes in β-cell activities observed under inflammatory conditions [58, 60] . Incubation of MIN6 or mouse-islet cells in the presence of exosomes isolated from the culture media of cytokine-treated β-cells did not affect insulin secretion but was found to trigger apoptosis [58] . To investigate whether this effect is linked to the transfer of miRNAs, a C. Elegans miRNA was transfected in MIN6 cells. This exogenous miRNA was indeed transferred via exosomes to untransfected MIN6 recipient cells. In addition, down-regulation in recipient cells of Ago2, a protein essential for the repressive activities of miRNAs, prevented apoptosis induced by exosomes released from cytokine-treated cells [58] .
The effect of cytokines such as IL-1β, TNFα and IFNγ on β-cells is concentration dependent. In fact, high levels of these inflammatory mediators induce apoptosis whereas low doses stimulate β-cell function and survival [63, 64] . With this concept in mind, Zhu and colleagues [62] Despite the fact that liver and adipose tissues liberate microvesicles in the circulation, there is currently no available information about their possible impact on β-cell function [70] [71] [72] [73] . Of interest, the release of miRNAs and exosomes from these insulin-sensitive tissues is increased under conditions of excess of lipids. Wang and colleagues [74] reported that the level of circulating miR-130b correlates with the body-mass index of obese individuals. This miRNA was also higher in blood, in adipocytes and, to a lesser extent, in muscles of obese mouse models. Interestingly, miR-130b was found to be released by the fat tissue and to be transferred to muscle cells were it represses the peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α), leading to a reduction in the expression of genes controlling the oxidative capacity [74] . These results suggest that miR-130b mediates a crosstalk between the adipocytes and muscle cells. The adipose tissue of mice fed high-fat diet or of ob/ob mice release also larger amounts of exosomes compared to control animals [70] . The exosomes derived from fat tissue of ob/ob mice are taken up by monocytes, leading to their activation and to the initiation of an inflammatory response. Moreover, injection of these exosomes in wild type mice led to the increase of plasma inflammatory cytokines and to the development of glucose intolerance and insulin resistance [70] . These effects may potentially by linked to differences in the miRNA content. Indeed, the exosomes produced from visceral adipose tissue of obese and lean individuals have been shown to display different miRNA profiles [75] . In liver, the production of microvesicles from mouse, rat and human hepatocytes is stimulated upon exposure to palmitate but not following incubation with the unsaturated fatty acid oleate [71] . In agreement with these observations, the blood of mice fed on a Western 
Circulating miRNAs as potential biomarkers of β-cell mass and/or function?
Besides being major regulators of gene expression, circulating miRNAs are now viewed as a novel generation of biomarkers to monitor the development of several diseases, including Type 1 and Type 2 diabetes [76] [77] [78] [79] . The advantages of using circulating miRNAs as biomarkers include convenient non-invasive methods for sample collection from different body fluids such as blood, urine, saliva and breast milk and high resistance to harsh laboratory conditions enabling long-term storage of the samples. However, it is very difficult to determine the precise origin of most circulating miRNAs and the level of the same miRNA is often affected by numerous physiological and pathophysiological conditions [80, 81] . β-cells constitute only a tiny fraction of the cells in our body and their contribution to the plasma miRNA profile is most probably marginal. Indeed, although very abundant in islet cells and highly enriched in the endocrine pancreas compared to other tissues, only about 1% of circulating miR-375 was estimated to originate from β-cells [82] . Erener and colleagues [83] attempted to monitor the loss of β-cells during the initial steps of diabetes development by measuring the level of miR-375 in plasma samples of two models of Type 1 diabetes, the NOD and streptozotocin-treated mice. In both models, circulating miR-375 levels were significantly increased prior to hyperglycemia and diabetes onset, probably reflecting massive β-cell death. A rise in miR-375 plasma levels in streptozotocin-treated mice as well as in hyperglycemic db/db mice lacking the leptin receptor was also observed in an independent study [82] . However, the circulating levels of this miRNA were decreased in two pre-diabetic but still normoglycemic animal models that are characterized by a strong expansion of the β-cell mass, the ob/ob mice and mice fed high-fat diet. miR-375 levels were also found to be higher in Type 1 diabetes patients, but not in MODY (Maturity Onset Diabetes of the Young) and in Type 2 diabetic patients compared to control subjects with no metabolic disorder.
Taken together, these results suggest that a rise in the plasma levels of miR-375 can be a good indicator of acute β-cell destruction, but cannot be used as a faithful reflection of β-cell function or mass. Additional studies are needed to determine if particular miRNAs coming from islet cells can mirror the loss of β-cell function and/or mass preceding the onset of Type 2 diabetes. Other alternative strategies may turn out to be more fruitful as the design of approaches to specifically isolate the exosomes released by β-cells or the measurement of other non-coding RNA classes, such as the long non-coding RNAs, that are also carried by blood vesicles and are likely to display a higher cell specificity [84] .
Open questions and future directions
The discovery of miRNAs has added a new layer of complexity to the mechanisms regulating the activities of the β-cells. Thanks to intensive efforts, our knowledge about the contribution of these non-coding RNAs in the differentiation and in the control of specialized functions of insulin-secreting cells is continuously improving. However, so far we have probably only scratched the surface of the problem and many aspects concerning the role of miRNAs remain to be elucidated. The studies carried out during the last decade were based on the assumption that changes in miRNA level are paralleled by corresponding modifications in miRNA activity and vice versa. We now know that this is not necessarily the case. In fact, only a small fraction of the miRNAs is bound to Ago2 [85] and in primary tissues most of them are associated with inactive low molecular weight Ago2 complexes [86] . This inactive miRNA reservoir can be recruited to high molecular weight complexes engaged on target repression upon activation of the phosphoinositide 3-kinase/AKT or of the mTOR signaling pathways. These findings indicate that the level of a given miRNA is not always predictive of his repressive activity. Thus, some of the changes in miRNA expression observed in the islets of diabetic animals may be without consequence for the β-cells while the silencing activity of other miRNAs may be induced without detectable modifications in the level of the noncoding RNAs.
Another aspect that has been largely neglected is the compartmentalization of certain miRNAs within the cells. In fact, miRNAs are usually viewed as cytosolic molecules.
However, several miRNAs, including miRNAs that play important roles in β-cell physiology, are present in other subcellular compartments including the mitochondria and the nucleus where they may accomplish specific and still incompletely understood regulatory tasks going beyond translational silencing (Fig.3 ) [87] [88] [89] . Moreover, there is emerging evidence for the association of specific miRNAs with the endoplasmic reticulum, the Golgi complex and multivesicular bodies, possibly explaining the selective release of some miRNAs from the cells [87, 90] . Another important factor that may influence the availability of the miRNAs is their capacity to interact with other RNA species such as long non-coding RNAs and circular RNAs (Fig.3) . The presence of multiple binding sites in these molecules has been proposed to sequester specific miRNAs and to prevent their interaction with endogenous targets [91] . For instance CiRS-7, a circular RNA that is expressed also in β-cells [92] , contains over 60 conserved binding sites for miR-7 and could potentially affect the availability of this important miRNA. Stoichiometric considerations and mathematical modeling indicate that efficient target competition can only be achieved for miRNA families displaying particular miRNA:target ratios [93, 94] . However, this general rule may have to be reconsidered in case of compartmentalization of the miRNAs, of their targets or of the competing RNAs.
These findings about the distribution and the mode of action of the miRNAs emphasize the need for novel experimental strategies permitting to monitor the changes in the activities rather than in the level of specific miRNAs. These approaches would provide a more reliable picture of the contribution of these non-coding RNAs in the regulation of β-cell functions.
Different issues about the role of miRNAs in intercellular communication remain also to be addressed. A key unsolved question concerns the process controlling the loading of miRNAs inside exosomes for subsequent release. Several studies have demonstrated major differences between the exosomal miRNA profile and the repertoire of the parental cells [48, 55, 57, 58, 95] . Moreover, the exosomal miRNA content can be selectively modified in response to physiological or pathological conditions [58, 69, 75] . This clearly points to the existence of sophisticated mechanisms permitting the retention of specific miRNAs inside the cells and the packaging of others in exosomes for extracellular release (Fig.2) . Different mechanisms have been proposed to explain the preferential release of certain miRNAs, but this issue has not yet been addressed in β-cells. In T lymphocytes, sumoylation has been shown to regulate the binding of the ribonucleoprotein hnRNPA2B1 to the GGAG sequence of certain miRNAs and to favor their trafficking toward exosomes [96] . In macrophages, an inverse correlation was observed between the level of the miRNAs sorted in exosomes and the cellular abundance of their respective targets, suggesting a selective release of miRNAs not involved in translational repression [97] . A different regulatory process was proposed in a study carried out in B cells in which the uridylation of the 3'end of the miRNAs was found to increase whereas the adenylation to decrease the release in exosomes [98] . Another mechanism potentially explaining the selective release of a subset of miRNAs rely on the existence of specific motifs in the 3'UTR of the target mRNAs that promote the export of mRNA/miRNA complexes into exosomes [99] . Finally, the abundance and/or the activity of two components of the miRNA silencing machinery, Ago2 and GW182, which are coreleased in exosomes was suggested to contribute to the regulation of the sorting of the miRNAs [100, 101] . Additional studies will be required to verify these observations and to determine whether the mechanisms directing the release of miRNAs are ubiquitously conserved or are specific to each cell type.
Another important issue that will need to be addressed concerns the potential heterogeneity of the circulating exosomes. Indeed, quantitative analysis of the miRNA/exosome ratio led to the puzzling conclusion that, if distributed homogenously across the entire exosome population, even the most abundant miRNAs would be present at less than a copy per vesicle [102] . This observation would suggest that most individual exosomes are unlikely to support intercellular miRNA-based communication. However, it can be hypothesized that the population of exosomes released by the cells is heterogeneous and includes rare miRNA-rich vesicles carrying the signals directed to other cells. The identification and the characterization of these exosome subpopulations would significantly improve our understanding of this newly discovered intercellular communication mode.
Conclusion
More than a decade of intensive investigations have attributed to miRNAs a central place in the mechanisms regulating β-cell gene expression. We now know that these small non-coding contributes to the silencing of Mct1 [25, 103] . 
